title: Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED].
authors.forename: D S
authors.initials: DS
authors.lastname: Goodin
authors.forename: E M
authors.initials: EM
authors.lastname: Frohman
authors.forename: G P
authors.initials: GP
authors.lastname: Garmany
authors.forename: J
authors.initials: J
authors.lastname: Halper
authors.forename: W H
authors.initials: WH
authors.lastname: Likosky
authors.forename: F D
authors.initials: FD
authors.lastname: Lublin
authors.forename: D H
authors.initials: DH
authors.lastname: Silberberg
authors.forename: W H
authors.initials: WH
authors.lastname: Stuart
authors.forename: S
authors.initials: S
authors.lastname: van den Noort
mesh_terms: D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D000068717:Glatiramer Acetate; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016899:Interferon-beta / Q000276:immunology / Q000627:therapeutic use*; D008942:Mitoxantrone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use; D010951:Plasma Exchange; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D008942:Mitoxantrone